Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
Diversion proctitis: Keep it or remove it!
Year: 2020
Source: 9th S-ECCO IBD Masterclass
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
Diversion proctocolitis
Year: 2019
Source: 4th H-ECCO IBD Masterclass
Authors: Monika Tripathi
Created: Tuesday, 28 May 2019, 3:32 PM
Proctitis, Post-operative IBD
Files: 1
Diverting stoma is enough!
Year: 2019
Source: 8th S-ECCO IBD Masterclass
Authors: Dieter Hahnloser
Created: Tuesday, 28 May 2019, 3:32 PM
Ileo anal pouch procedure, Stoma
Files: 1
Do i really need a histopathologist?
Year: 2020
Source: 5th H-ECCO IBD Masterclass
Authors: James Lindsay
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
Does size matter? How long should the Pouch be?
Year: 2018
Source: 7th S-ECCO IBD Masterclass
Authors: Colombo Francesco
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicentre retrospective study
Year: 2018
Source: ECCO'18 Vienna
Authors: Kopylov Uri
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP001: European Crohn’s and Colitis Organisation topical review on environmental factors in IBD
Year: 2017
Source: ECCO'17 Barcelona
Authors: Maaser C.
Environmental factors, Microbiota, Smoking
Files: 1
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patients
Year: 2016
Source: ECCO'16 DOP
Authors: Taylor K.
calprotectin, capsule endoscopy, Crohn's Disease, genetics
Files: 1
DOP002: Molecular Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease by Serum Protein Analysis: Results from the UNITI-1 and UNITI-2 Phase 3 Induction Studies
Year: 2016
Source: ECCO'16 DOP
Authors: Li K.
Crohn's Disease, ustekinumab, immunology
Files: 1
DOP002: Trends in small bowel resections for Crohn’s disease with and without short bowel syndrome in the era of biologics
Year: 2017
Source: ECCO'17 Barcelona
Authors: Colombel J.
Natural history
Files: 1
DOP002:Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
Year: 2018
Source: ECCO'18 Vienna
Authors: Vermeire Séverine
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP003: Gene Expression Profiling Indicates Similar Molecular Pathways Are Active in Adult And Pediatric Ulcerative Colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Li K.
genetics, Ulcerative Colitis, paediatric
Files: 1
DOP003: Proximal disease extension in patients with limited Ulcerative Colitis: a Danish population-based inception cohort
Year: 2017
Source: ECCO'17 Barcelona
Authors: Burisch J.
Natural history, Ulcerative colitis, Montreal classification
Files: 1
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world belgian cohort study
Year: 2018
Source: ECCO'18 Vienna
Authors: Liefferinckx Claire
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP004: Epigenetic control of colonic epithelial antigen processing, barrier function, and the microbiome via methyl-CpG binding domain protein 2
Year: 2016
Source: ECCO'16 DOP
Authors: Jones G.
epithelial cell, genetics, lymphocyte, microbiota, epigenetics
Files: 1
DOP004: Ethnicity and country of birth are associated with phenotypic differences in patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Spekhorst L.
environmental factors, Genetic factors, Crohn's disease, Ulcerative colitis, Montreal Classification
Files: 1
DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACY
Year: 2018
Source: ECCO'18 Vienna
Authors: Bossuyt Peter
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP005: Proximal disease extension in limited Ulcerative Colitis: A systematic review and meta-analysis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Roda G.
Natural history, Ulcerative colitis, Montreal classification
Files: 1
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists
Year: 2018
Source: ECCO'18 Vienna
Authors: Russell Cohen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1